Previous 10 | Next 10 |
Turning Point Therapeutics ( TPTX +0.6% ) signs an agreement with Zai Lab ( ZLAB +4.3% ) for Turning Point’s lead drug candidate, repotrectinib for lung cancer. More news on: Turning Point Therapeutics, Inc., Zai Lab Limited, Healthcare stocks news, Read more ...
Zai Lab Granted Exclusive Rights to Develop and Commercialize Repotrectinib in Greater China Turning Point to Receive $25 Million Upfront, Potential for Future Milestones of up to $151 Million and Royalties TRIDENT-1 Phase 2 Registrational Study of Repotrectinib to Open Addit...
Zai Lab Granted Exclusive Rights to Develop and Commercialize Repotrectinib in Greater China Turning Point to Receive $25 Million Upfront, Potential for Future Milestones of up to $151 Million and Royalties TRIDENT-1 Phase 2 Registrational Study of Repotrectinib to Open Addit...
This article is part of a series that provides an ongoing analysis of the changes made to BAMCO Inc.’s 13F stock portfolio on a quarterly basis. It is based on Ron Baron’s regulatory 13F Form filed on 05/15/2020. The 13F portfolio value decreased ~22% from $26.19B to $20.41B th...
The following slide deck was published by Zai Lab in conjunction with this Read more ...
Market Pulse The question of whether it's a new bull market rally or just an intermittent bear market rally doomed to end later this year will most likely be decided late in the third quarter or during the fourth quarter when enough evidence on the durability of the recovery pace is forthcom...
Zai Lab (NASDAQ: ZLAB ) announces positive topline results from the NORA study, the Phase 3 study of ZEJULA (niraparib) as a maintenance therapy in Chinese patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to ...
- The NORA study meets all primary and secondary endpoints - Largest randomized clinical trial (RCT) in ovarian cancer ever conducted in China - Individualized starting dose regimen shown to be effective with improved safety profile in Chinese patients SHA...
Coronavirus Pandemic Tianjin CanSino Biologics (HK: 6185) published positive results from a China Phase I trial of its COVID-19 vaccine in the prestigious British journal, The Lancet. In the study, the Ad5 vectored COVID-19 vaccine was immunogenic at 28 days post-vaccination with only mild...
SHANGHAI and SAN FRANCISCO , May 19, 2020 /PRNewswire/ -- Zai Lab Limited (NASDAQ: ZLAB), an innovative commercial stage biopharmaceutical company, today announced dosing of the first Chinese patient in the global ATTACK (Acinetobacter Treatment Trial Against Colistin) Phase 3 registrat...
News, Short Squeeze, Breakout and More Instantly...
First and only NMPA-approved subcutaneous (SC) injectable providing additional flexibility and optionality for gMG patients in China Consistent clinical benefit and safety profile of efgartigimod SC compared to IV demonstrated in Phase 3 ADAPT-SC study Zai Lab Limited (NASDAQ: Z...
Manuscript represents the first publication from China’s gynecology oncology field to be published in Cell Publication highlights first-time learnings about the landscape of ovarian cancer microenvironment stratified by HRD and how a PARP inhibitor perturbs it Data suggest ...
2024-07-05 18:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...